Late-onset hypogonadism: a concept comes of age

Andrology

Volumn 8, Issue 6, 2020, Pages 1506-1511

  Nieschlag, E ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

guidelines; history; late onset hypogonadism; testosterone

Indexed keywords

TESTOSTERONE; BIOLOGICAL MARKER;

ANDROGEN THERAPY; CLIMACTERIUM; CLINICIAN; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOGONADISM; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TESTOSTERONE BLOOD LEVEL; ADVERSE EVENT; AGED; ANIMAL; BLOOD; CLINICAL DECISION MAKING; EUNUCHOIDISM; HORMONE SUBSTITUTION; MALE; MIDDLE AGED; ONSET AGE; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

AGE OF ONSET; AGED; ANIMALS; BIOMARKERS; CLINICAL DECISION-MAKING; EUNUCHISM; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 85075454323     PISSN: 20472919     EISSN: 20472927     Source Type: Journal    
DOI: 10.1111/andr.12719     Document Type: Review

References (56)

1. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM & McKinlay JB. (2004) Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 89, 5920–5926.
2. Baillargeon J, Urban RJ, Kuo YF, Holmes HM, Raji MA, Morgentaler A, Howrey BT, Lin YL & Ottenbacher KJ. (2015) Screening and monitoring in men prescribed testosterone therapy in the US., 2001–2010. Public Health Rep 130, 143–152.
3. Baillargeon J, Urban RJ, Kuo YF, Ottenbacher KJ, Raji MA, Du F, Lin YL & Goodwin JS. (2014) Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother 48, 1138–1144.
4. Baillargeon J, Kuo Y-F, Westra JR, Urban RJ & Goodwin JS. (2018) Testosterone prescribing in the United States 2002–2016. JAMA 320, 200–202.
5. Berthold AA. (1849) Über die Transplantation der Hoden. Archiv für Anatomie Physiologie und Wissenschaftliche Medicin 42–46.
6. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC & Yialamas MA. (2018) Testosterone therapy in men with hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 103, 1715–1744.
7. Brown-Séquard E. (1889) The effects produced on man by subcutaneous injections of a liquid obtained from the testicles of animals. Lancet 20, 105–107.
8. Butenandt A & Hanisch G. (1935) Über Testosteron. Umwandlung des Dehydroandrosterons in Androstendiol und Testosteron; ein Weg zur Darstellung des Testosterons aus Cholesterin. Hoppe-Seyler’s Zeitschrift für Physiologie und Chemie 237, 89–97.
9. Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E & Maggi M. (2014) Cardiovascular risk associated with testosterone-boosting medications: asystematic review and meta-analysis. Expert Opin Drug Saf 13, 1327–1351.
10. Corona G, Maseroli E, Rastrelli G, Francomano D, Aversa A, Hackett GI, Ferri S, Sforza A & Maggi M. (2016) Is late-onset hypogonadotropic hypogonadism a specific age-dependent disease, or merely an epiphenomenon caused by accumulating disease-burden? Minerva Endocrinol 41, 196–210.
11. Cussons AJ, Bhagat CI, Fletcher SJ & Walsh JP. (2002) Brown-Séquard revisited: a lesson from history on the placebo effect of androgen treatment. Med J Aust 177, 678–679.
12. David K, Dingemanse E, Freud J & Laquer E. (1935) Über krystallinisches männliches Hormon aus Hoden (Testosteron), wirksamer als aus Harn oder aus Cholesterin bereitetes Androsteron. Hoppe-Seyler’s Zeitschrift für Physiologische Chemie 233, 281–283.
13. Dean JD, McMahon CG, Guay AT, Morgentaler A, et al. (2015) The ISSEM (International Society for Sexual Medicine) Process of care for the assessment and management of testosterone deficiency in adult men. J Sex Med 12, 1660–1686.
14. Dimopoulou C, Ceausu J, Depypere H, Lambrinoudaki I, Mueck A, Pérez-López F, Rees M, Van der Schouw Y, Senturk L, Simonsini T, Stevenson J, Stute P & Goulis DG. (2016) EMAS (Europ. Menopause and Andropause Society) position statement: testosterone replacement therapy in the aging male. Maturitas 84, 94–99.
15. Dohle GR, Arver S, Bettocchi C, Kliesch S,Punab M, & de Ronde W. (2012–2017). EAU Guidelines on male hypogonadism. https://uroweb.org (last visited July 15, 2019).
16. FDA Drug Safety Communication. FDA cautions about using testosterone products for low testosterone due to aging: requires labeling change to inform of possible increased risk of heart attack and stroke with use. FDA Drug Safety Communication. January 31, 2014.
17. EMA (European Medicines Agency). PRAC review does not confirm increase in heart problems with testosterone medicines. European Medicines Agency October 10, 2014.
18. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF Jr & Hoover RN. (2014) Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE 9, e85805.
19. Gabrielsen JS, Najari BB, Alukal JP & Eisenberg ML. (2016) Trends in Testosterone Prescription and Public Health Concerns. Urol Clin North Am 43, 261–271.
20. Harman SM, Metter EJ, Tobin JD, Pearson J & Blackman MR. (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86, 724–731.
21. Jasuja GK, Bhasin S, Reisman JI, Berlowitz DR & Rose AJ. (2015) Ascertainment of testosterone prescribing practices in the VA. Med Care 53, 746–752.
22. Kelleher S, Conway AJ & Handelsman DJ. (2004) Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 89, 3813–3817.
23. Landau RL. (1951) The concept of the male climacteric. Med Clin North Am 35, 279–288.
24. Layton JB, Li D, Meier CR, Sharpless JL, Stürmer T, Jick SS & Brookhart MA. (2014) Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab 99, 835–842.
25. Morales A & Lunenfeld B. (2001) Androgen replacement therapy in aging men with secondary hypogonadism. Aging Male 4, 151–162.
26. Morales A & Lunenfeld B. (2002) Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 5, 74–86.
27. Morales A, Bebb RA, Manjoo P, Assimakopoulos P, Axler J, Collier C, Elliott S, Goldenberg L, Gottesman I, Grober ED, Guyatt GH, Holmes DT, Lee JC; Canadian Men’s Health Foundation Multidisciplinary Guidelines Task Force on Testosterone Deficiency. (2015) Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline. CMAJ 187, 1369–1377.
28. Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M & Traish AM. (2015) Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc 90, 224–251.
29. Muram D, Zhang X, Cui Z & Matsumoto AM. (2015) Use of hormone testing for the diagnosis and evaluation of male hypogonadism and monitoring of testosterone therapy: application of hormone testing guideline recommendations in clinical practice. J Sex Med 12, 1886–1894.
30. Nieschlag E & Loriaux DL. (1972) Radioimmunoassay for plasma testosterone. Z Klin Chem Klin Biochem 10, 164–168.
31. Nieschlag E, Lammers U, Freischem CW, Langer K & Wickings EJ. (1982) Reproductive functions in young fathers and grandfathers. J Clin Endocrinol Metab 55, 676–681.
32. Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, Webb SM & Wu FC. (2004) Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 10, 409–419.
33. Nieschlag E & Nieschlag S. (2019) Endocrine History: The history of discovery, synthesis and development of testosterone for clinical use. Eur J Endocrinol 180, R201–R212.
34. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W & Wu FCW. (2005a) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl 28, 125–127.
35. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W & Wu FCW. (2005b) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Aging Male 8, 56–58.
36. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W & Wu FCW. (2005c) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Eur Urol 48, 1–4.
37. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W & Wu FCW. (2005d) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Repromed Endokrinol 2, 269–271.
38. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W & Wu FCW. (2006a) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl 27, 135–137.
39. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W & Wu FCW. (2006b) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Malta Med J 18, 7–9.
40. Ruzicka L & Wettstein A. (1935) Synthetische Darstellung des Testikelhormons Testosteron (Androsten 3-on-17-ol). Helv Chim Acta 18, 1264–1275.
41. Storrs C. (2014) Increasing testosterone use raises safety concerns. Too many men are getting testosterone for the wrong reasons. Scientific American.
42. Veldhuis JD, Urban RJ, Lizarralde G, Johnson ML & Iranmanesh A. (1992) Attenuation of luteinizing hormone secretory burst amplitude as a proximate basis for the hypoandrogenism of healthy aging in men. J Clin Endocrinol Metab 75, 707–713.
43. Vigen R, O'Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME, Rumsfeld JS & Ho PM. (2013) Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310, 1829–1836.
44. Walker K. (1938) The male climacteric. Postgrad Med J 150, 120–123.
45. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W & Wu FCW. (2008a) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 159, 507–514.
46. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W & Wu FCW. (2008b) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. J Androl 30, 1–9.
47. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W & Wu FCW. (2009a) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. J Androl 32, 1–10.
48. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W & Wu FCW. (2009b) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Int J Impot Res 21, 1–8.
49. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W & Wu FCW. (2009c) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Aging Male 12, 5–12.
50. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W & Wu FCW. (2009d) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur Urol 55, 121–130.
51. Werner AA. (1946) The male climacteric. Report of 273 cases. J Am Med Assoc 132, 188–194.
52. Wu FCW, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean MEJ, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F & Huhtaniemi IT. (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 363, 123–35.
53. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S & Vanderschueren D; European Male Aging Study Group. (2008) Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 93, 2737–2745.
54. Xu L, Freeman G, Cowling BJ & Schooling CM. (2013) Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 11, 108.
55. Zitzmann M & Nieschlag E. (2003) Hypogonadism in the elderly man: Rational diagnosis and therapy. Der Internist 44, 1313–1321.
56. Zitzmann M, Faber S & Nieschlag E. (2006) Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 91, 4335–4343.